Home/Filings/4/0000921895-20-003088

4//SEC Filing

BVF I GP LLC 4

Accession 0000921895-20-003088

CIK 0001750284other

View on SEC.gov Company Profile

Filed

Nov 19, 7:00 PM ET

Accepted

Nov 20, 8:02 PM ET

Size

71.2 KB

Accession

0000921895-20-003088

Insider Transaction Report

Form 4

Period: 2020-11-18

Olema Pharmaceuticals, Inc.OLMA

BVF PARTNERS L P/IL

DirectorOther

Transactions

Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−1,129,404→ 0 total
→ Common stock, $0.0001 par value (1,129,404 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+446,425$8,482,075→ 2,523,265 total
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+613,918$11,664,442→ 3,392,663 total
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+74,991$1,424,829→ 436,082 total
Conversion
Common stock, $0.0001 par value
2020-11-19+881,156→ 881,156 total
Conversion
Common stock, $0.0001 par value
2020-11-19+522,403→ 2,076,840 total
Award
Stock Option (Right to buy)
2020-11-18+21,520→ 21,520 total(indirect: See footnote)
Exercise: $19.00Exp: 2030-11-17→ Common stock, $0.0001 par value (21,520 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+101,784→ 287,692 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−889,186→ 0 total
→ Common stock, $0.0001 par value (889,186 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−73,399→ 0 total
→ Common stock, $0.0001 par value (73,399 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+185,908→ 185,908 total
Conversion
Common stock, $0.0001 par value
2020-11-19+1,129,404→ 1,129,404 total
Conversion
Common stock, $0.0001 par value
2020-11-19+889,186→ 2,018,590 total
Conversion
Common stock, $0.0001 par value
2020-11-19+760,155→ 2,778,745 total
Conversion
Common stock, $0.0001 par value
2020-11-19+73,399→ 361,091 total
Conversion
Series C Convertible Preferred Stock
2020-11-19−522,403→ 0 total
→ Common stock, $0.0001 par value (522,403 underlying)
Conversion
Series B Convertible Preferred Stock
2020-11-19−101,784→ 0 total
→ Common stock, $0.0001 par value (101,784 underlying)
Conversion
Series B Convertible Preferred Stock
2020-11-19−673,281→ 0 total
→ Common stock, $0.0001 par value (673,281 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−760,155→ 0 total
→ Common stock, $0.0001 par value (760,155 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−185,908→ 0 total
→ Common stock, $0.0001 par value (185,908 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+673,281→ 1,554,437 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−881,156→ 0 total
→ Common stock, $0.0001 par value (881,156 underlying)

BIOTECHNOLOGY VALUE FUND II LP

DirectorOther

Transactions

Conversion
Common stock, $0.0001 par value
2020-11-19+1,129,404→ 1,129,404 total
Conversion
Common stock, $0.0001 par value
2020-11-19+522,403→ 2,076,840 total
Conversion
Common stock, $0.0001 par value
2020-11-19+185,908→ 185,908 total
Conversion
Common stock, $0.0001 par value
2020-11-19+73,399→ 361,091 total
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+74,991$1,424,829→ 436,082 total
Conversion
Common stock, $0.0001 par value
2020-11-19+101,784→ 287,692 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−1,129,404→ 0 total
→ Common stock, $0.0001 par value (1,129,404 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+613,918$11,664,442→ 3,392,663 total
Conversion
Common stock, $0.0001 par value
2020-11-19+881,156→ 881,156 total
Conversion
Common stock, $0.0001 par value
2020-11-19+673,281→ 1,554,437 total
Award
Stock Option (Right to buy)
2020-11-18+21,520→ 21,520 total(indirect: See footnote)
Exercise: $19.00Exp: 2030-11-17→ Common stock, $0.0001 par value (21,520 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−881,156→ 0 total
→ Common stock, $0.0001 par value (881,156 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−185,908→ 0 total
→ Common stock, $0.0001 par value (185,908 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+446,425$8,482,075→ 2,523,265 total
Conversion
Series C Convertible Preferred Stock
2020-11-19−760,155→ 0 total
→ Common stock, $0.0001 par value (760,155 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−522,403→ 0 total
→ Common stock, $0.0001 par value (522,403 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−73,399→ 0 total
→ Common stock, $0.0001 par value (73,399 underlying)
Conversion
Series B Convertible Preferred Stock
2020-11-19−889,186→ 0 total
→ Common stock, $0.0001 par value (889,186 underlying)
Conversion
Series B Convertible Preferred Stock
2020-11-19−101,784→ 0 total
→ Common stock, $0.0001 par value (101,784 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+760,155→ 2,778,745 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−673,281→ 0 total
→ Common stock, $0.0001 par value (673,281 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+889,186→ 2,018,590 total

BVF I GP LLC

DirectorOther

Transactions

Conversion
Common stock, $0.0001 par value
2020-11-19+881,156→ 881,156 total
Conversion
Common stock, $0.0001 par value
2020-11-19+185,908→ 185,908 total
Conversion
Series C Convertible Preferred Stock
2020-11-19−760,155→ 0 total
→ Common stock, $0.0001 par value (760,155 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−522,403→ 0 total
→ Common stock, $0.0001 par value (522,403 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+1,129,404→ 1,129,404 total
Conversion
Common stock, $0.0001 par value
2020-11-19+760,155→ 2,778,745 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−673,281→ 0 total
→ Common stock, $0.0001 par value (673,281 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+522,403→ 2,076,840 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−101,784→ 0 total
→ Common stock, $0.0001 par value (101,784 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+889,186→ 2,018,590 total
Conversion
Common stock, $0.0001 par value
2020-11-19+673,281→ 1,554,437 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−889,186→ 0 total
→ Common stock, $0.0001 par value (889,186 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−881,156→ 0 total
→ Common stock, $0.0001 par value (881,156 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+613,918$11,664,442→ 3,392,663 total
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+446,425$8,482,075→ 2,523,265 total
Conversion
Common stock, $0.0001 par value
2020-11-19+101,784→ 287,692 total
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+74,991$1,424,829→ 436,082 total
Award
Stock Option (Right to buy)
2020-11-18+21,520→ 21,520 total(indirect: See footnote)
Exercise: $19.00Exp: 2030-11-17→ Common stock, $0.0001 par value (21,520 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−1,129,404→ 0 total
→ Common stock, $0.0001 par value (1,129,404 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−185,908→ 0 total
→ Common stock, $0.0001 par value (185,908 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−73,399→ 0 total
→ Common stock, $0.0001 par value (73,399 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+73,399→ 361,091 total

BVF II GP LLC

DirectorOther

Transactions

Conversion
Series C Convertible Preferred Stock
2020-11-19−73,399→ 0 total
→ Common stock, $0.0001 par value (73,399 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+446,425$8,482,075→ 2,523,265 total
Conversion
Common stock, $0.0001 par value
2020-11-19+881,156→ 881,156 total
Award
Stock Option (Right to buy)
2020-11-18+21,520→ 21,520 total(indirect: See footnote)
Exercise: $19.00Exp: 2030-11-17→ Common stock, $0.0001 par value (21,520 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+101,784→ 287,692 total
Conversion
Common stock, $0.0001 par value
2020-11-19+73,399→ 361,091 total
Conversion
Series C Convertible Preferred Stock
2020-11-19−522,403→ 0 total
→ Common stock, $0.0001 par value (522,403 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−1,129,404→ 0 total
→ Common stock, $0.0001 par value (1,129,404 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−760,155→ 0 total
→ Common stock, $0.0001 par value (760,155 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+1,129,404→ 1,129,404 total
Conversion
Common stock, $0.0001 par value
2020-11-19+522,403→ 2,076,840 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−881,156→ 0 total
→ Common stock, $0.0001 par value (881,156 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−185,908→ 0 total
→ Common stock, $0.0001 par value (185,908 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+673,281→ 1,554,437 total
Conversion
Common stock, $0.0001 par value
2020-11-19+760,155→ 2,778,745 total
Conversion
Common stock, $0.0001 par value
2020-11-19+185,908→ 185,908 total
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+74,991$1,424,829→ 436,082 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−889,186→ 0 total
→ Common stock, $0.0001 par value (889,186 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+889,186→ 2,018,590 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−673,281→ 0 total
→ Common stock, $0.0001 par value (673,281 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+613,918$11,664,442→ 3,392,663 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−101,784→ 0 total
→ Common stock, $0.0001 par value (101,784 underlying)

Biotechnology Value Trading Fund OS LP

DirectorOther

Transactions

Conversion
Series B Convertible Preferred Stock
2020-11-19−889,186→ 0 total
→ Common stock, $0.0001 par value (889,186 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+446,425$8,482,075→ 2,523,265 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−881,156→ 0 total
→ Common stock, $0.0001 par value (881,156 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+101,784→ 287,692 total
Conversion
Series C Convertible Preferred Stock
2020-11-19−73,399→ 0 total
→ Common stock, $0.0001 par value (73,399 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+73,399→ 361,091 total
Conversion
Series C Convertible Preferred Stock
2020-11-19−760,155→ 0 total
→ Common stock, $0.0001 par value (760,155 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+522,403→ 2,076,840 total
Conversion
Common stock, $0.0001 par value
2020-11-19+889,186→ 2,018,590 total
Conversion
Common stock, $0.0001 par value
2020-11-19+760,155→ 2,778,745 total
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+613,918$11,664,442→ 3,392,663 total
Conversion
Common stock, $0.0001 par value
2020-11-19+673,281→ 1,554,437 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−1,129,404→ 0 total
→ Common stock, $0.0001 par value (1,129,404 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+1,129,404→ 1,129,404 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−185,908→ 0 total
→ Common stock, $0.0001 par value (185,908 underlying)
Conversion
Series B Convertible Preferred Stock
2020-11-19−673,281→ 0 total
→ Common stock, $0.0001 par value (673,281 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−522,403→ 0 total
→ Common stock, $0.0001 par value (522,403 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+881,156→ 881,156 total
Conversion
Common stock, $0.0001 par value
2020-11-19+185,908→ 185,908 total
Award
Stock Option (Right to buy)
2020-11-18+21,520→ 21,520 total(indirect: See footnote)
Exercise: $19.00Exp: 2030-11-17→ Common stock, $0.0001 par value (21,520 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+74,991$1,424,829→ 436,082 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−101,784→ 0 total
→ Common stock, $0.0001 par value (101,784 underlying)

BVF Partners OS Ltd.

DirectorOther

Transactions

Conversion
Common stock, $0.0001 par value
2020-11-19+1,129,404→ 1,129,404 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−101,784→ 0 total
→ Common stock, $0.0001 par value (101,784 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+613,918$11,664,442→ 3,392,663 total
Conversion
Common stock, $0.0001 par value
2020-11-19+73,399→ 361,091 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−185,908→ 0 total
→ Common stock, $0.0001 par value (185,908 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+101,784→ 287,692 total
Conversion
Common stock, $0.0001 par value
2020-11-19+881,156→ 881,156 total
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+446,425$8,482,075→ 2,523,265 total
Conversion
Series C Convertible Preferred Stock
2020-11-19−760,155→ 0 total
→ Common stock, $0.0001 par value (760,155 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+185,908→ 185,908 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−673,281→ 0 total
→ Common stock, $0.0001 par value (673,281 underlying)
Conversion
Series B Convertible Preferred Stock
2020-11-19−889,186→ 0 total
→ Common stock, $0.0001 par value (889,186 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+760,155→ 2,778,745 total
Conversion
Common stock, $0.0001 par value
2020-11-19+522,403→ 2,076,840 total
Conversion
Series C Convertible Preferred Stock
2020-11-19−73,399→ 0 total
→ Common stock, $0.0001 par value (73,399 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+889,186→ 2,018,590 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−1,129,404→ 0 total
→ Common stock, $0.0001 par value (1,129,404 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−881,156→ 0 total
→ Common stock, $0.0001 par value (881,156 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+74,991$1,424,829→ 436,082 total
Conversion
Common stock, $0.0001 par value
2020-11-19+673,281→ 1,554,437 total
Conversion
Series C Convertible Preferred Stock
2020-11-19−522,403→ 0 total
→ Common stock, $0.0001 par value (522,403 underlying)
Award
Stock Option (Right to buy)
2020-11-18+21,520→ 21,520 total(indirect: See footnote)
Exercise: $19.00Exp: 2030-11-17→ Common stock, $0.0001 par value (21,520 underlying)

BVF GP HOLDINGS LLC

DirectorOther

Transactions

Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−185,908→ 0 total
→ Common stock, $0.0001 par value (185,908 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−1,129,404→ 0 total
→ Common stock, $0.0001 par value (1,129,404 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+760,155→ 2,778,745 total
Conversion
Common stock, $0.0001 par value
2020-11-19+1,129,404→ 1,129,404 total
Conversion
Common stock, $0.0001 par value
2020-11-19+522,403→ 2,076,840 total
Conversion
Common stock, $0.0001 par value
2020-11-19+73,399→ 361,091 total
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+613,918$11,664,442→ 3,392,663 total
Conversion
Common stock, $0.0001 par value
2020-11-19+881,156→ 881,156 total
Conversion
Common stock, $0.0001 par value
2020-11-19+673,281→ 1,554,437 total
Conversion
Common stock, $0.0001 par value
2020-11-19+889,186→ 2,018,590 total
Conversion
Common stock, $0.0001 par value
2020-11-19+101,784→ 287,692 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−101,784→ 0 total
→ Common stock, $0.0001 par value (101,784 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−522,403→ 0 total
→ Common stock, $0.0001 par value (522,403 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−760,155→ 0 total
→ Common stock, $0.0001 par value (760,155 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+185,908→ 185,908 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−673,281→ 0 total
→ Common stock, $0.0001 par value (673,281 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+446,425$8,482,075→ 2,523,265 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−881,156→ 0 total
→ Common stock, $0.0001 par value (881,156 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−73,399→ 0 total
→ Common stock, $0.0001 par value (73,399 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+74,991$1,424,829→ 436,082 total
Award
Stock Option (Right to buy)
2020-11-18+21,520→ 21,520 total(indirect: See footnote)
Exercise: $19.00Exp: 2030-11-17→ Common stock, $0.0001 par value (21,520 underlying)
Conversion
Series B Convertible Preferred Stock
2020-11-19−889,186→ 0 total
→ Common stock, $0.0001 par value (889,186 underlying)

LAMPERT MARK N

DirectorOther

Transactions

Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−1,129,404→ 0 total
→ Common stock, $0.0001 par value (1,129,404 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+613,918$11,664,442→ 3,392,663 total
Conversion
Common stock, $0.0001 par value
2020-11-19+673,281→ 1,554,437 total
Conversion
Common stock, $0.0001 par value
2020-11-19+73,399→ 361,091 total
Conversion
Common stock, $0.0001 par value
2020-11-19+881,156→ 881,156 total
Conversion
Series C Convertible Preferred Stock
2020-11-19−73,399→ 0 total
→ Common stock, $0.0001 par value (73,399 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−760,155→ 0 total
→ Common stock, $0.0001 par value (760,155 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+101,784→ 287,692 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−673,281→ 0 total
→ Common stock, $0.0001 par value (673,281 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+760,155→ 2,778,745 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−185,908→ 0 total
→ Common stock, $0.0001 par value (185,908 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+889,186→ 2,018,590 total
Conversion
Series C Convertible Preferred Stock
2020-11-19−522,403→ 0 total
→ Common stock, $0.0001 par value (522,403 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+185,908→ 185,908 total
Conversion
Common stock, $0.0001 par value
2020-11-19+1,129,404→ 1,129,404 total
Award
Stock Option (Right to buy)
2020-11-18+21,520→ 21,520 total(indirect: See footnote)
Exercise: $19.00Exp: 2030-11-17→ Common stock, $0.0001 par value (21,520 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+522,403→ 2,076,840 total
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+446,425$8,482,075→ 2,523,265 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−881,156→ 0 total
→ Common stock, $0.0001 par value (881,156 underlying)
Conversion
Series B Convertible Preferred Stock
2020-11-19−889,186→ 0 total
→ Common stock, $0.0001 par value (889,186 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+74,991$1,424,829→ 436,082 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−101,784→ 0 total
→ Common stock, $0.0001 par value (101,784 underlying)

BIOTECHNOLOGY VALUE FUND L P

DirectorOther

Transactions

Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+74,991$1,424,829→ 436,082 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−881,156→ 0 total
→ Common stock, $0.0001 par value (881,156 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+522,403→ 2,076,840 total
Conversion
Common stock, $0.0001 par value
2020-11-19+101,784→ 287,692 total
Award
Stock Option (Right to buy)
2020-11-18+21,520→ 21,520 total(indirect: See footnote)
Exercise: $19.00Exp: 2030-11-17→ Common stock, $0.0001 par value (21,520 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−522,403→ 0 total
→ Common stock, $0.0001 par value (522,403 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+613,918$11,664,442→ 3,392,663 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−185,908→ 0 total
→ Common stock, $0.0001 par value (185,908 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+881,156→ 881,156 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−1,129,404→ 0 total
→ Common stock, $0.0001 par value (1,129,404 underlying)
Conversion
Series B Convertible Preferred Stock
2020-11-19−889,186→ 0 total
→ Common stock, $0.0001 par value (889,186 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−73,399→ 0 total
→ Common stock, $0.0001 par value (73,399 underlying)
Conversion
Series B Convertible Preferred Stock
2020-11-19−673,281→ 0 total
→ Common stock, $0.0001 par value (673,281 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−760,155→ 0 total
→ Common stock, $0.0001 par value (760,155 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+760,155→ 2,778,745 total
Conversion
Common stock, $0.0001 par value
2020-11-19+673,281→ 1,554,437 total
Conversion
Common stock, $0.0001 par value
2020-11-19+889,186→ 2,018,590 total
Conversion
Common stock, $0.0001 par value
2020-11-19+185,908→ 185,908 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−101,784→ 0 total
→ Common stock, $0.0001 par value (101,784 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+1,129,404→ 1,129,404 total
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+446,425$8,482,075→ 2,523,265 total
Conversion
Common stock, $0.0001 par value
2020-11-19+73,399→ 361,091 total

BVF INC/IL

DirectorOther

Transactions

Conversion
Common stock, $0.0001 par value
2020-11-19+881,156→ 881,156 total
Conversion
Common stock, $0.0001 par value
2020-11-19+1,129,404→ 1,129,404 total
Conversion
Common stock, $0.0001 par value
2020-11-19+889,186→ 2,018,590 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−101,784→ 0 total
→ Common stock, $0.0001 par value (101,784 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+613,918$11,664,442→ 3,392,663 total
Conversion
Common stock, $0.0001 par value
2020-11-19+101,784→ 287,692 total
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+74,991$1,424,829→ 436,082 total
Award
Stock Option (Right to buy)
2020-11-18+21,520→ 21,520 total(indirect: See footnote)
Exercise: $19.00Exp: 2030-11-17→ Common stock, $0.0001 par value (21,520 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−1,129,404→ 0 total
→ Common stock, $0.0001 par value (1,129,404 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−760,155→ 0 total
→ Common stock, $0.0001 par value (760,155 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−522,403→ 0 total
→ Common stock, $0.0001 par value (522,403 underlying)
Purchase
Common stock, $0.0001 par value
2020-11-19$19.00/sh+446,425$8,482,075→ 2,523,265 total
Conversion
Series B Convertible Preferred Stock
2020-11-19−889,186→ 0 total
→ Common stock, $0.0001 par value (889,186 underlying)
Conversion
Series B Convertible Preferred Stock
2020-11-19−673,281→ 0 total
→ Common stock, $0.0001 par value (673,281 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−881,156→ 0 total
→ Common stock, $0.0001 par value (881,156 underlying)
Conversion
Series C Convertible Preferred Stock
2020-11-19−73,399→ 0 total
→ Common stock, $0.0001 par value (73,399 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+760,155→ 2,778,745 total
Conversion
Common stock, $0.0001 par value
2020-11-19+185,908→ 185,908 total
Conversion
Series A-1 Convertible Preferred Stock
2020-11-19−185,908→ 0 total
→ Common stock, $0.0001 par value (185,908 underlying)
Conversion
Common stock, $0.0001 par value
2020-11-19+522,403→ 2,076,840 total
Conversion
Common stock, $0.0001 par value
2020-11-19+73,399→ 361,091 total
Conversion
Common stock, $0.0001 par value
2020-11-19+673,281→ 1,554,437 total

Footnotes (10)

[F1]This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
[F10]Effective upon the closing of the IPO on November 19, 2020, as provided by the Issuer, each share of the Issuer's Series C Convertible Preferred Stock held by the Reporting Persons automatically converted on a one-for-one basis into the Issuer's Common Stock. Prior to the IPO, each such share of Preferred Stock was convertible at any time into shares of Common Stock and had no expiration date.
[F2]Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
[F3]Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
[F4]Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
[F5]Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
[F6]The shares subject to the option vest in a series of 12 successive equal monthy installments measured from June 1, 2020, subject to the Mr. Hrustanovic's continuous service on the Issuer's board of directors through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Mr. Hrustanovic's continuous service through such vesting date.
[F7]The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to Mr. Hrustanovic's continuous service on the Issuer's board of directors through each applicable vesting date.
[F8]Effective upon the closing of the Issuer's initial public offering (the "IPO") on November 19, 2020, as provided by the Issuer, each share of the Issuer's Series A-1 Convertible Preferred Stock held by the Reporting Persons automatically converted on a one-for-one basis into the Issuer's Common Stock. Prior to the IPO, each such shares of Preferred Stock was convertible at any time into shares of Common Stock and had no expiration date.
[F9]Effective upon the closing of the IPO on November 19, 2020, as provided by the Issuer, each share of the Issuer's Series Series B Convertible Preferred Stock held by the Reporting Persons automatically converted on a one-for-one basis into the Issuer's Common Stock. Prior to the IPO, each such share of Preferred Stock was convertible at any time into shares of Common Stock and had no expiration date.

Documents

1 file

4
form407422olma_11202020.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

Olema Pharmaceuticals, Inc.

CIK 0001750284

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001803805

Filing Metadata

Form type: 4
Filed: Nov 19, 7:00 PM ET
Accepted: Nov 20, 8:02 PM ET
Size: 71.2 KB

View on SEC.gov